TPL2-NPM-p53 pathway monitors nucleolar stress

A. Eliopoulos, S. Volarevic
{"title":"TPL2-NPM-p53 pathway monitors nucleolar stress","authors":"A. Eliopoulos, S. Volarevic","doi":"10.18632/ONCOSCIENCE.254","DOIUrl":null,"url":null,"abstract":"Serving as the cellular factory for the biogenesis of ribosomes (the molecular machines responsible for the decoding of mRNAs to proteins), the nucleolus controls a vast array of physiological processes including cell growth and proliferation. It thus comes as no surprise that inherited and acquired abnormalities in ribosome biogenesis can lead to tumorigenesis and that changes in size and number of the nucleoli, which are assumed to reflect the rate of ribosome production, have long been recognized as feature of a large number of tumor types. To safeguard against the potentially tumorigenic effects of deregulated ribosome biogenesis, cells activate the p53 tumor suppressor by re-directing the ribosomal protein (RP) L5/RPL11/5S rRNA pre-ribosomal complex from ribosome biogenesis to HDM2 binding, alleviating its inhibitory effect over p53 [1]. \n \nHowever, it has long been appreciated that upon exposure of cells to distinct genotoxic agents that also perturb nucleolar structure and ribosome biogenesis, the nucleolar proteins nucleophosmin (NPM) and alternative reading frame (ARF) tumor suppressor are engaged to activate p53. Thus, oncogene-induced replication stress and genotoxic insults ensue DNA damage responses that impair the nucleolar interaction of ARF with NPM, leading to the release of ARF to the nucleoplasm where it binds HDM2 and inhibits HDM2-mediated degradation of p53 [2]. NPM is also mobilized to the nucleoplasm, although with somewhat slower kinetics, to associate with free, p53-bound or de novo synthesized HDM2 [2]. The ensuing accumulation of p53 is required for cell cycle arrest, senescence or apoptosis of damaged cells. The central role of NPM in these nucleolus-orchestrated responses is further highlighted by the fact that NPM mutations which render it cytoplasmic are associated with genomic instability and the development of hematopoietic malignancies such as acute myeloid leukemia (AML) [2]. \n \nA recent study by Kanellis et al. [3] provides novel insight into the intricate management of p53 activation upon “nucleolar stress” by identifying Tumor Progression Locus 2 (TPL2; also known as COT and MAP3K8) as a physical and functional partner of NPM. TPL2 has mostly been appreciated as a cytoplasmic kinase involved in the wiring of pro-inflammatory signal transduction [4]. Kanellis et al. have found that in malignant cells and normal fibroblasts a fraction of TPL2 resides in the nucleolus where it associates with and phosphorylates a pool of NPM molecules at Thr199. As this phosphorylation event is required for NPM ubiquitination and proteasomal degradation, TPL2 appears to participate in the maintenance of physiological levels of NPM. Upon genotoxic stress this NPM pool becomes de-phosphorylated by activated PP1β [5], stabilizes and translocates to the nucleoplasm where it sequesters HDM2 away from p53 leading to a robust p53 response (Figure ​(Figure1).1). Consistent with this novel TPL2 function in p53 activation, several human cancers display reduced expression of TPL2 [4, 6] and recently published genetic evidence in the mouse suggests that this kinase operates in epithelial cells as suppressor of malignant transformation [6, 7]. \n \n \n \nFigure 1 \n \nSchematic representation of a novel TPL2/NPM/HDM2/p53 pathway activated upon nucleolar stress [3] \n \n \n \nHow do these observations fit in the aforementioned NPM-centered model? The work by Kanellis et al. suggests that when TPL2 levels are reduced, the fraction of NPM that becomes phosphorylated diminishes. This in turn results in a limited pool of phosphorylated NPM available for PP1β-mediated de-phosphorylation upon nucleolar stress, causing insufficient mobilization of NPM to the nucleoplasm thereby allowing HDM2 to maintain significant control over p53 (Figure ​(Figure1).1). In line with these observations, NPM or TPL2 silencing impairs stress-induced p53 stabilization in vitro and in vivo [2, 3, 6]. \n \nThis work hints to an unprecedented duality in TPL2 function that depends on subcellular topology: transduction of pro-inflammatory signals in the cytoplasm and inhibition of tumorigenic pathways in the nucleus. However, a number of outstanding questions remain unanswered. How do these distinct TPL2 functions intertwine to achieve control of processes relevant to tumorigenesis such as cell cycle arrest, apoptosis and senescence? What is the relationship between nucleolar TPL2 and oncogene-induced ARF or the RPL5/RPL11/5S rRNA/HDM2/p53 signaling pathway? Do these pathways sense distinct stress-induced nucleolar lesions and do they synergize in p53 activation and tumor suppression? \n \nAn abundance of evidence has shown that inherited abnormalities in ribosome function can lead to tumorigenesis. Diamond Blackfan Anemia (DBA) is a rare inherited bone marrow failure syndrome caused by alterations in several RP genes and it typifies a group of disorders called ribosomopathies that are linked to mutations in genes encoding RPs or other factors involved in ribosome biogenesis [8]. DBA itself predisposes to myelodysplastic syndromes (MDS) which may further progress to AML. As errors in ribosome biosynthesis activate the RPL5/RPL11/5S rRNA/HDM2/p53 signaling pathway, it has been suggested that the selection of cells that loose expression of wild-type p53 or acquire mutations in p53 or other signaling components of the RPL5/RPL11/5S rRNA/HDM2 complex may allow escape from the ribosome biogenesis stress-imposed checkpoint, thereby facilitating tumor progression. As AML cells show approximately 2-fold reduction in TPL2 mRNA levels [4], mutational inactivation of p53 and cytoplasmic localization of NPM [2], it can be postulated that the TPL2/NPM/HDM2/p53 response might also, alone or in synergy with the RPL5/RPL11/5S rRNA/HDM2/p53 signaling pathway, inhibit progression of pre-neoplastic MDS cells to AML, a possibility that warrants further investigations. \n \nThe identification of TPL2 as a novel component of the nucleolar stress response may therefore contribute to better understanding of the pathogenesis of human diseases and the pursuit of TPL2 signaling will no doubt continue to provide invaluable insight into the complex biological functions of the nucleolus.","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"516 1","pages":"892 - 893"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/ONCOSCIENCE.254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Serving as the cellular factory for the biogenesis of ribosomes (the molecular machines responsible for the decoding of mRNAs to proteins), the nucleolus controls a vast array of physiological processes including cell growth and proliferation. It thus comes as no surprise that inherited and acquired abnormalities in ribosome biogenesis can lead to tumorigenesis and that changes in size and number of the nucleoli, which are assumed to reflect the rate of ribosome production, have long been recognized as feature of a large number of tumor types. To safeguard against the potentially tumorigenic effects of deregulated ribosome biogenesis, cells activate the p53 tumor suppressor by re-directing the ribosomal protein (RP) L5/RPL11/5S rRNA pre-ribosomal complex from ribosome biogenesis to HDM2 binding, alleviating its inhibitory effect over p53 [1]. However, it has long been appreciated that upon exposure of cells to distinct genotoxic agents that also perturb nucleolar structure and ribosome biogenesis, the nucleolar proteins nucleophosmin (NPM) and alternative reading frame (ARF) tumor suppressor are engaged to activate p53. Thus, oncogene-induced replication stress and genotoxic insults ensue DNA damage responses that impair the nucleolar interaction of ARF with NPM, leading to the release of ARF to the nucleoplasm where it binds HDM2 and inhibits HDM2-mediated degradation of p53 [2]. NPM is also mobilized to the nucleoplasm, although with somewhat slower kinetics, to associate with free, p53-bound or de novo synthesized HDM2 [2]. The ensuing accumulation of p53 is required for cell cycle arrest, senescence or apoptosis of damaged cells. The central role of NPM in these nucleolus-orchestrated responses is further highlighted by the fact that NPM mutations which render it cytoplasmic are associated with genomic instability and the development of hematopoietic malignancies such as acute myeloid leukemia (AML) [2]. A recent study by Kanellis et al. [3] provides novel insight into the intricate management of p53 activation upon “nucleolar stress” by identifying Tumor Progression Locus 2 (TPL2; also known as COT and MAP3K8) as a physical and functional partner of NPM. TPL2 has mostly been appreciated as a cytoplasmic kinase involved in the wiring of pro-inflammatory signal transduction [4]. Kanellis et al. have found that in malignant cells and normal fibroblasts a fraction of TPL2 resides in the nucleolus where it associates with and phosphorylates a pool of NPM molecules at Thr199. As this phosphorylation event is required for NPM ubiquitination and proteasomal degradation, TPL2 appears to participate in the maintenance of physiological levels of NPM. Upon genotoxic stress this NPM pool becomes de-phosphorylated by activated PP1β [5], stabilizes and translocates to the nucleoplasm where it sequesters HDM2 away from p53 leading to a robust p53 response (Figure ​(Figure1).1). Consistent with this novel TPL2 function in p53 activation, several human cancers display reduced expression of TPL2 [4, 6] and recently published genetic evidence in the mouse suggests that this kinase operates in epithelial cells as suppressor of malignant transformation [6, 7]. Figure 1 Schematic representation of a novel TPL2/NPM/HDM2/p53 pathway activated upon nucleolar stress [3] How do these observations fit in the aforementioned NPM-centered model? The work by Kanellis et al. suggests that when TPL2 levels are reduced, the fraction of NPM that becomes phosphorylated diminishes. This in turn results in a limited pool of phosphorylated NPM available for PP1β-mediated de-phosphorylation upon nucleolar stress, causing insufficient mobilization of NPM to the nucleoplasm thereby allowing HDM2 to maintain significant control over p53 (Figure ​(Figure1).1). In line with these observations, NPM or TPL2 silencing impairs stress-induced p53 stabilization in vitro and in vivo [2, 3, 6]. This work hints to an unprecedented duality in TPL2 function that depends on subcellular topology: transduction of pro-inflammatory signals in the cytoplasm and inhibition of tumorigenic pathways in the nucleus. However, a number of outstanding questions remain unanswered. How do these distinct TPL2 functions intertwine to achieve control of processes relevant to tumorigenesis such as cell cycle arrest, apoptosis and senescence? What is the relationship between nucleolar TPL2 and oncogene-induced ARF or the RPL5/RPL11/5S rRNA/HDM2/p53 signaling pathway? Do these pathways sense distinct stress-induced nucleolar lesions and do they synergize in p53 activation and tumor suppression? An abundance of evidence has shown that inherited abnormalities in ribosome function can lead to tumorigenesis. Diamond Blackfan Anemia (DBA) is a rare inherited bone marrow failure syndrome caused by alterations in several RP genes and it typifies a group of disorders called ribosomopathies that are linked to mutations in genes encoding RPs or other factors involved in ribosome biogenesis [8]. DBA itself predisposes to myelodysplastic syndromes (MDS) which may further progress to AML. As errors in ribosome biosynthesis activate the RPL5/RPL11/5S rRNA/HDM2/p53 signaling pathway, it has been suggested that the selection of cells that loose expression of wild-type p53 or acquire mutations in p53 or other signaling components of the RPL5/RPL11/5S rRNA/HDM2 complex may allow escape from the ribosome biogenesis stress-imposed checkpoint, thereby facilitating tumor progression. As AML cells show approximately 2-fold reduction in TPL2 mRNA levels [4], mutational inactivation of p53 and cytoplasmic localization of NPM [2], it can be postulated that the TPL2/NPM/HDM2/p53 response might also, alone or in synergy with the RPL5/RPL11/5S rRNA/HDM2/p53 signaling pathway, inhibit progression of pre-neoplastic MDS cells to AML, a possibility that warrants further investigations. The identification of TPL2 as a novel component of the nucleolar stress response may therefore contribute to better understanding of the pathogenesis of human diseases and the pursuit of TPL2 signaling will no doubt continue to provide invaluable insight into the complex biological functions of the nucleolus.
TPL2-NPM-p53通路监测核仁应激
作为核糖体(负责将mrna解码为蛋白质的分子机器)生物发生的细胞工厂,核仁控制着包括细胞生长和增殖在内的大量生理过程。因此,核糖体生物发生中的遗传和获得性异常可导致肿瘤发生并不令人惊讶,核仁的大小和数量的变化被认为反映了核糖体产生的速度,长期以来一直被认为是许多肿瘤类型的特征。为了防止失控的核糖体生物发生的潜在致瘤作用,细胞通过将核糖体蛋白(RP) L5/RPL11/5S rRNA前核糖体复合体从核糖体生物发生重定向到HDM2结合来激活p53肿瘤抑制因子,减轻其对p53的抑制作用[1]。然而,人们早就认识到,当细胞暴露于不同的基因毒性物质时,核仁结构和核糖体的生物发生也会受到干扰,核仁蛋白核磷蛋白(NPM)和替代阅读框(ARF)肿瘤抑制因子参与激活p53。因此,癌基因诱导的复制应激和基因毒性损伤会导致DNA损伤反应,损害ARF与NPM的核仁相互作用,导致ARF释放到核质中,在核质中与HDM2结合,抑制HDM2介导的p53降解[2]。NPM也被动员到核质中,与游离的、p53结合的或从头合成的HDM2结合[2],尽管动力学稍慢。随后p53的积累是细胞周期阻滞、衰老或受损细胞凋亡所必需的。NPM的细胞质突变与基因组不稳定性和造血恶性肿瘤(如急性髓性白血病(AML))的发展相关,这一事实进一步强调了NPM在这些核仁协调反应中的核心作用[2]。Kanellis等人最近的一项研究[3]通过鉴定肿瘤进展位点2 (Tumor Progression Locus 2, TPL2;也被称为COT和MAP3K8)作为NPM的物理和功能伙伴。TPL2主要被认为是参与促炎信号转导的细胞质激酶[4]。Kanellis等人发现,在恶性细胞和正常成纤维细胞中,TPL2的一部分存在于核核中,在那里它与Thr199位点的NPM分子池结合并磷酸化。由于这种磷酸化事件是NPM泛素化和蛋白酶体降解所必需的,因此TPL2似乎参与了NPM生理水平的维持。在基因毒性胁迫下,这个NPM池被活化的PP1β去磷酸化[5],稳定并易位到核质中,在那里它将HDM2从p53分离出来,导致p53的强烈反应(图(图1))。与TPL2在p53激活中的新功能一致,几种人类癌症显示TPL2表达降低[4,6],最近发表的小鼠遗传证据表明,该激酶在上皮细胞中作为恶性转化的抑制因子[6,7]。图1核仁胁迫下激活的新型TPL2/NPM/HDM2/p53通路示意图[3]这些观察结果如何符合上述以NPM为中心的模型?Kanellis等人的研究表明,当TPL2水平降低时,NPM被磷酸化的部分减少。这反过来导致有限的磷酸化NPM可用于核核应激时pp1 β介导的去磷酸化,导致NPM对核质的动员不足,从而使HDM2保持对p53的显著控制(图(图1))。与这些观察结果一致,NPM或TPL2沉默在体外和体内都会损害应激诱导的p53稳定[2,3,6]。这项工作提示了TPL2功能中前所未有的两重性,它依赖于亚细胞拓扑:细胞质中促炎信号的转导和细胞核中致瘤途径的抑制。然而,一些悬而未决的问题仍未得到解答。这些不同的TPL2功能如何相互交织以实现对肿瘤发生相关过程的控制,如细胞周期阻滞、细胞凋亡和衰老?核仁TPL2与癌基因诱导的ARF或RPL5/RPL11/5S rRNA/HDM2/p53信号通路有何关系?这些通路是否感知不同的应激诱导的核仁病变,它们是否在p53激活和肿瘤抑制中协同作用?大量证据表明,核糖体功能的遗传异常可导致肿瘤发生。 Diamond Blackfan Anemia (DBA)是一种罕见的遗传性骨髓衰竭综合征,由几个RP基因的改变引起,它是一组被称为核糖体病的疾病的典型,这种疾病与编码RP的基因突变或参与核糖体生物发生的其他因素有关[8]。DBA本身易患骨髓增生异常综合征(MDS), MDS可能进一步发展为AML。由于核糖体生物合成中的错误激活了RPL5/RPL11/5S rRNA/HDM2/p53信号通路,因此有研究表明,选择野生型p53表达松散或p53或RPL5/RPL11/5S rRNA/HDM2复合体的其他信号组分突变的细胞可能使其逃脱核糖体生物发生施加的应激检查点,从而促进肿瘤的进展。由于AML细胞表现出约2倍的TPL2 mRNA水平降低[4]、p53突变失活和NPM的细胞质定位[2],我们可以假设TPL2/NPM/HDM2/p53应答也可能单独或与RPL5/RPL11/5S rRNA/HDM2/p53信号通路协同作用,抑制肿瘤前MDS细胞向AML的进展,这一可能性值得进一步研究。因此,鉴定TPL2作为核仁应激反应的一个新组成部分可能有助于更好地理解人类疾病的发病机制,而对TPL2信号的追求无疑将继续为核仁复杂的生物学功能提供宝贵的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信